Key facts
- This page summarizes James L. Heppell's Form 4 filing for Skye Bioscience, Inc. (SKYE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Sep 2021, 16:02.
James L. Heppell - 14 Sep 2021 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)
- Reporting relationship
- Director
- Issuer ticker
- SKYE
- Reported as of
- 14 Sep 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ James L. Heppell
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
James L. Heppell filed Form 4 for Skye Bioscience, Inc. (SKYE) on 16 Sep 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SKYE
transaction
Derivative
Director Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +150,000
- Change %
- +12%
- Price
- $0.000000
- Shares after
- 1,350,000
- Date
- 14 Sep 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
- Exercise price
- $0.1200
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The Option shall be exercisable for a price of $0.12 per Option Share in twelve equal monthly installments such that all the Option Shares shall vest in twelve months.